AZORRA LLC Launches Revolutionary Staghorn Calculus Management Solution, Offering Hope to Millions

Fort Lauderdale, FL – October 26, 2023 – AZORRA LLC, a forward-thinking medical device company based in Fort Lauderdale, Florida, today announced the launch of its groundbreaking new product specifically designed to address the complex challenges of staghorn calculi – large, branched kidney stones. These stones, shaped like stag horns, can cause excruciating pain, kidney damage, and life-threatening complications. For years, treatment has been invasive, lengthy, and often incomplete, leaving patients facing multiple procedures and prolonged recovery times. AZORRA's solution promises a new era in effective, minimally invasive management of these debilitating conditions. AZORRA LLC, located at 201 E Las Olas Blvd Ste 2250, is built on a commitment to innovation and patient-centric care. Founded by a team of experienced medical device professionals and driven by a desire to improve patient outcomes, the company has dedicated years to researching, developing, and rigorously testing this game-changing technology. “We saw a real gap in the market,” explains Dr. Elias Vance, Chief Medical Officer at AZORRA LLC. “Current methods for tackling staghorn stones are often brutal – open surgery, extensive ureteroscopy. Patients deserve better. We wanted to create something that significantly reduced pain, recovery time, and the need for multiple interventions.” The Problem with Staghorn Calculi Staghorn calculi are particularly challenging due to their size, complex branching patterns, and location within the kidney. Unlike smaller kidney stones that can sometimes pass on their own, staghorn stones rarely do. Traditional treatment options typically involve: Percutaneous Nephrolithotomy (PCNL): This involves making a large incision in the back to directly access the kidney and remove the stone. It's effective, but carries risks of bleeding, infection, and damage to surrounding organs. Recovery is often lengthy, requiring hospitalization for several days. Ureteroscopy: This procedure involves inserting a thin, flexible scope through the urethra and bladder to reach the kidney stone. While less invasive than PCNL, it can be difficult to navigate the complex branching patterns of a staghorn stone, and multiple sessions may be needed. Extracorporeal Shock Wave Lithotripsy (ESWL): This uses shock waves to break the stone into smaller pieces. However, ESWL isn't always effective for large, dense staghorn stones, and may require other procedures to remove the fragments. These methods often leave behind stone fragments, increasing the risk of recurrence. The combined impact on patients' quality of life and healthcare costs is substantial. “We listened to the needs of urologists and patients alike,” says Sarah Chen, AZORRA’s VP of Product Development. “The biggest requests were for a solution that was both effective at completely removing the stone and significantly reduced the burden on the patient.” AZORRA’s Innovative Solution: Precision and Control AZORRA’s new product, currently undergoing final regulatory approvals, is a revolutionary single-use device designed to be used in conjunction with standard endoscopic techniques. It’s not meant to replace existing procedures, but rather to enhance their effectiveness. Here's how it works: The device features a uniquely designed, flexible articulating tip equipped with miniaturized, high-frequency ultrasonic technology. This allows surgeons to precisely target and fragment even the most complex staghorn stone formations within the kidney. Key benefits of AZORRA's technology include: Precise Fragmentation: The ultrasonic technology delivers focused energy directly to the stone, breaking it down into smaller, easily removable fragments. This minimizes damage to surrounding kidney tissue. Enhanced Visibility: The device’s slim profile and integrated irrigation system provide excellent visibility during the procedure, allowing surgeons to navigate complex anatomy with confidence. Complete Stone Removal: By effectively fragmenting the entire stone, AZORRA’s technology significantly reduces the risk of residual fragments and recurrence. Minimally Invasive: Used through a standard endoscopic approach, the device minimizes incisions and reduces patient trauma. Reduced Procedure Time: Faster and more efficient fragmentation can shorten overall procedure time, benefiting both patients and healthcare providers. Single-Use Design: Eliminates the need for sterilization, reducing the risk of cross-contamination and streamlining workflow. “We’ve spent years refining the ultrasonic frequencies and the articulating tip design,” explains Dr. Vance. “The goal was to create a device that felt like an extension of the surgeon’s hand, providing precise control and optimal performance.” Clinical Trials and Future Outlook Preliminary clinical data from ongoing trials have been exceptionally promising. Early results show a significant reduction in procedure time, a higher rate of complete stone removal, and fewer complications compared to traditional methods. Patients have reported less pain and a faster recovery time. AZORRA LLC is committed to further research and development to expand the applications of its ultrasonic technology to other areas of urology and beyond. The company envisions a future where minimally invasive procedures are the standard of care for all types of kidney stones. “We’re not just selling a product; we’re offering hope to millions of people who suffer from kidney stones,” says Sarah Chen. “We believe our technology has the potential to transform the way staghorn calculi are treated, improving the lives of patients around the world.” Contact: AZORRA LLC 201 E Las Olas Blvd Ste 2250 Fort Lauderdale, FL, 33301-4449 UNITED STATES 318-468-6734 [website address - removed for example]